AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

AJ201 (rosolutamide) is described as an investigational oral small molecule in Phase 3 development for spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease. The article fragment calls it the only known investigational therapy for SBMA in Phase 3 development worldwide and says it is designed to address multiple disease mechanisms; it provides no trial results or further details about the referenced submission.